72 related articles for article (PubMed ID: 21574093)
1. Development of an AlphaScreen-based high-throughput screening assay for inhibitors of human vascular endothelial growth factor receptor-3.
Wang K; Yang R; Xu J; Zhang Y; Zhu L; Lin J; Huang B
J Immunoassay Immunochem; 2011; 32(3):219-32. PubMed ID: 21574093
[TBL] [Abstract][Full Text] [Related]
2. Suppression of lymphangiogenesis in human lymphatic endothelial cells by simultaneously blocking VEGF-C and VEGF-D/VEGFR-3 with norcantharidin.
Liu ZY; Qiu HO; Yuan XJ; Ni YY; Sun JJ; Jing W; Fan YZ
Int J Oncol; 2012 Nov; 41(5):1762-72. PubMed ID: 22922710
[TBL] [Abstract][Full Text] [Related]
3. Soluble Expression and Purification of the Catalytic Domain of Human Vascular Endothelial Growth Factor Receptor 2 in Escherichia coli.
Wei J; Cao X; Zhou S; Chen C; Yu H; Zhou Y; Wang P
J Microbiol Biotechnol; 2015 Aug; 25(8):1227-33. PubMed ID: 25907066
[TBL] [Abstract][Full Text] [Related]
4. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
5. VEGF-A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells.
Doi Y; Yashiro M; Yamada N; Amano R; Noda S; Hirakawa K
Ann Surg Oncol; 2012 Aug; 19(8):2733-43. PubMed ID: 22207048
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth.
Laakkonen P; Waltari M; Holopainen T; Takahashi T; Pytowski B; Steiner P; Hicklin D; Persaud K; Tonra JR; Witte L; Alitalo K
Cancer Res; 2007 Jan; 67(2):593-9. PubMed ID: 17234768
[TBL] [Abstract][Full Text] [Related]
7. Neuropilin-1 modulates vascular endothelial growth factor-induced poly(ADP-ribose)-polymerase leading to reduced cerebrovascular apoptosis.
Mey L; Hörmann M; Schleicher N; Reuter P; Dönges S; Kinscherf R; Gassmann M; Gerriets T; Al-Fakhri N
Neurobiol Dis; 2013 Nov; 59():111-25. PubMed ID: 23816753
[TBL] [Abstract][Full Text] [Related]
8. [Establishment of homogeneous time-resolved fluorescence immunoassay for high throughput screening of protein tyrosine kinase inhibitors].
Li XG; Wang GF; Zhang JY; Wu SY; Xu W; Wu SG; Zhang JJ
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Aug; 29(8):1612-4. PubMed ID: 19726307
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor C stimulates progression of human gastric cancer via both autocrine and paracrine mechanisms.
Kodama M; Kitadai Y; Tanaka M; Kuwai T; Tanaka S; Oue N; Yasui W; Chayama K
Clin Cancer Res; 2008 Nov; 14(22):7205-14. PubMed ID: 19010837
[TBL] [Abstract][Full Text] [Related]
10. A widely applicable, high-throughput TR-FRET assay for the measurement of kinase autophosphorylation: VEGFR-2 as a prototype.
Moshinsky DJ; Ruslim L; Blake RA; Tang F
J Biomol Screen; 2003 Aug; 8(4):447-52. PubMed ID: 14567797
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor receptor 2 (VEGFR-2) signalling activity in paediatric pilocytic astrocytoma is restricted to tumour endothelial cells.
Sikkema AH; de Bont ES; Molema G; Dimberg A; Zwiers PJ; Diks SH; Hoving EW; Kamps WA; Peppelenbosch MP; den Dunnen WF
Neuropathol Appl Neurobiol; 2011 Aug; 37(5):538-48. PubMed ID: 21208252
[TBL] [Abstract][Full Text] [Related]
12. Correlation between lymph node metastasis and the expression of VEGF-C, VEGF-D and VEGFR-3 in T1 lung adenocarcinoma.
Maekawa S; Iwasaki A; Shirakusa T; Enatsu S; Kawakami T; Kuroki M; Kuroki M
Anticancer Res; 2007; 27(6A):3735-41. PubMed ID: 17970036
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of anti-VEGFR-3 specific scFv antibodies as potential therapeutic and diagnostic tools for tumor lymph-angiogenesis.
Zehnder-Fjällman AH; Marty C; Halin C; Hohn A; Schibli R; Ballmer-Hofer K; Schwendener RA
Oncol Rep; 2007 Oct; 18(4):933-41. PubMed ID: 17786357
[TBL] [Abstract][Full Text] [Related]
14. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.
Joukov V; Pajusola K; Kaipainen A; Chilov D; Lahtinen I; Kukk E; Saksela O; Kalkkinen N; Alitalo K
EMBO J; 1996 Jan; 15(2):290-98. PubMed ID: 8617204
[TBL] [Abstract][Full Text] [Related]
15. MAZ51, an indolinone that inhibits endothelial cell and tumor cell growth in vitro, suppresses tumor growth in vivo.
Kirkin V; Thiele W; Baumann P; Mazitschek R; Rohde K; Fellbrich G; Weich H; Waltenberger J; Giannis A; Sleeman JP
Int J Cancer; 2004 Dec; 112(6):986-93. PubMed ID: 15386354
[TBL] [Abstract][Full Text] [Related]
16. Distribution of vascular endothelial growth factor receptor-3/Flt4 mRNA in adult rat central nervous system.
Hou Y; Shin YJ; Han EJ; Choi JS; Park JM; Cha JH; Choi JY; Lee MY
J Chem Neuroanat; 2011 Sep; 42(1):56-64. PubMed ID: 21703344
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer.
Von Marschall Z; Scholz A; Stacker SA; Achen MG; Jackson DG; Alves F; Schirner M; Haberey M; Thierauch KH; Wiedenmann B; Rosewicz S
Int J Oncol; 2005 Sep; 27(3):669-79. PubMed ID: 16077915
[TBL] [Abstract][Full Text] [Related]
18. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody.
Pytowski B; Goldman J; Persaud K; Wu Y; Witte L; Hicklin DJ; Skobe M; Boardman KC; Swartz MA
J Natl Cancer Inst; 2005 Jan; 97(1):14-21. PubMed ID: 15632376
[TBL] [Abstract][Full Text] [Related]
19. A selective and oral small molecule inhibitor of vascular epithelial growth factor receptor (VEGFR)-2 and VEGFR-1 inhibits neovascularization and vascular permeability.
Patel N; Sun L; Moshinsky D; Chen H; Leahy KM; Le P; Moss KG; Wang X; Rice A; Tam D; Laird AD; Yu X; Zhang Q; Tang C; McMahon G; Howlett A
J Pharmacol Exp Ther; 2003 Sep; 306(3):838-45. PubMed ID: 12766257
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2.
Roberts N; Kloos B; Cassella M; Podgrabinska S; Persaud K; Wu Y; Pytowski B; Skobe M
Cancer Res; 2006 Mar; 66(5):2650-7. PubMed ID: 16510584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
